Leveraging agentic AI and interconnected data for true patient 360

The global agentic AI in life sciences market is projected to grow from an estimated $530 million in 2024 to nearly $5 billion by 2030. This panel report captures a vital discussion on how autonomous AI systems and comprehensive data integration are transforming patient care and pharmaceutical operations.

This exclusive report synthesizes a panel discussion with senior leaders from Gilead, J&J Innovative Medicine, Regeneron, and Merck. They explored how to achieve a dynamic, real-time Patient 360 view by combining interconnected data with Agentic AI, autonomous systems capable of initiating actions and learning from outcomes.

The industry is at an inflection point; discover how moving from static data integration to autonomous AI can unlock new value across the pharmaceutical lifecycle!

Key highlights from the discussion

• The evolution of Patient 360: Learn how the definition has expanded beyond EMRs and claims data to include wearables, social determinants of health, behavioral data, and environmental factors.
• The 50% factor: Panelists emphasized that social determinants, behaviors, and environment drive ~50% of patient outcomes, a segment largely untapped by current AI systems. Agentic AI is key to bridging this gap.
• From reactive to proactive: Understand the industry's shift from complaining about data coverage to leveraging AI to extract profound value from available data, enabling predictive and prescriptive care.
• Applications across the value chain: See how Agentic AI impacts everything from drug discovery and clinical trial optimization to the convergence of commercial and medical functions and personalized patient engagement.
• The path forward: The panel outlines a future vision of autonomous data integration, predictive patient pathways, and scalable real-world evidence, all underpinned by robust ethical and governance frameworks.

Insights from industry leaders

This report features insights from a panel of senior leaders from major pharmaceutical companies and captures their forward-thinking view of the opportunities and challenges ahead. Here is what the panelists had to say:

"The industry has moved from complaining about data to focusing on what we can do with that data."

"The scope of Patient 360 keeps growing away from us," reflecting the exponential increase in data sources that Agentic AI is designed to handle.

"Success hinges on aligning technology, tech stack, and data strategy."

FAQs